Want to see BBIO full AI Analyst Report?
Total Valuation
BridgeBio Pharma has a market cap or net worth of $15.61B. The enterprise value is $17.27K.
Market Cap$15.61B
Enterprise Value$17.27K
Share Statistics
BridgeBio Pharma has 195,487,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding195,487,470
Owned by Insiders3.96%
Owned by Institutions35.03%
Financial Efficiency
BridgeBio Pharma’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is -108.46%.
Return on Equity (ROE)0.35
Return on Assets (ROA)-0.78
Return on Invested Capital (ROIC)-108.46%
Return on Capital Employed (ROCE)-0.88
Revenue Per Employee598.42K
Profits Per Employee-864.04K
Employee Count839
Asset Turnover0.54
Inventory Turnover1.06
Valuation Ratios
The current PE Ratio of BridgeBio Pharma is ―. BridgeBio Pharma’s PEG ratio is -0.64.
PE Ratio―
PS Ratio30.05
PB Ratio-7.27
Price to Fair Value-7.27
Price to FCF-33.75
Price to Operating Cash Flow-26.65
PEG Ratio-0.64
Income Statement
In the last 12 months, BridgeBio Pharma had revenue of 502.08M and earned -729.31M in profits. Earnings per share was -3.79.
Revenue502.08M
Gross Profit473.81M
Operating Income-569.09M
Pretax Income-734.99M
Net Income-729.31M
EBITDA-672.88M
Earnings Per Share (EPS)-3.79
Cash Flow
In the last 12 months, operating cash flow was -586.61M and capital expenditures -5.51M, giving a free cash flow of -592.12M billion.
Operating Cash Flow-586.61M
Free Cash Flow-592.12M
Free Cash Flow per Share-3.03
Dividends & Yields
BridgeBio Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.65
52-Week Price Change62.91%
50-Day Moving Average77.19
200-Day Moving Average72.71
Relative Strength Index (RSI)46.12
Average Volume (3m)4.02M
Important Dates
BridgeBio Pharma upcoming earnings date is Oct 29, 2026, After Close (Confirmed).
Last Earnings DateAug 10, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
BridgeBio Pharma as a current ratio of 2.62, with Debt / Equity ratio of -99.15%
Current Ratio2.62
Quick Ratio2.52
Debt to Market Cap0.18
Net Debt to EBITDA-3.21
Interest Coverage Ratio-10.72
Taxes
In the past 12 months, BridgeBio Pharma has paid 555.00K in taxes.
Income Tax555.00K
Effective Tax Rate>-0.01
Enterprise Valuation
BridgeBio Pharma EV to EBITDA ratio is -25.63, with an EV/FCF ratio of -38.58.
EV to Sales34.35
EV to EBITDA-25.63
EV to Free Cash Flow-38.58
EV to Operating Cash Flow-38.67
Balance Sheet
BridgeBio Pharma has $720.16M in cash and marketable securities with $2.49B in debt, giving a net cash position of -$1.77B billion.
Cash & Marketable Securities$720.16M
Total Debt$2.49B
Net Cash-$1.77B
Net Cash Per Share-$9.07
Tangible Book Value Per Share-$10.67
Margins
Gross margin is 93.14%, with operating margin of -113.35%, and net profit margin of -145.26%.
Gross Margin93.14%
Operating Margin-113.35%
Pretax Margin-146.39%
Net Profit Margin-145.26%
EBITDA Margin-134.02%
EBIT Margin-135.81%
Analyst Forecast
The average price target for BridgeBio Pharma is $108.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$108.56
Price Target Upside29.21% Upside
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast202.39%
EPS Growth Forecast12.83%